New insulin study aims to tame type 2 diabetes when pills fall short
NCT ID NCT04980027
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a long-acting insulin called glargine (brand name Toujeo) in 228 adults with type 2 diabetes whose blood sugar was still too high despite taking oral diabetes medications. The main goal was to see how safe the insulin was, including any low blood sugar episodes. Researchers also checked whether it helped lower blood sugar levels and improved patients' satisfaction with their treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
insulin glargine (Toujeo)
What this could lead to
If successful, this could confirm that starting insulin glargine is a safe and effective option for people with type 2 diabetes who need better blood sugar control.
What could go wrong
This is a single-arm, phase 4 study with no comparison group, so results are less definitive. Side effects like low blood sugar (hypoglycemia) are possible with insulin therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational site Number 3560003
Jaipur, 302017, India
-
Investigational site Number 3560013
Nashik, 422002, India